Alexander Vos Appointed Chairman of Scenic Biotech’s Board of Directors
Wednesday February 12, 2025 – Scenic Biotech announced the appointment of Alexander Vos as Chairman to its Board of Directors. With more than 30 years of CEO and Board member experience across the biotech industry, Alexander brings a track record of growing and advancing biopharmaceutical companies, with a focus on rare and orphan diseases and cell and gene therapies. Scenic Biotech would also like to thank our previous Chairman, Philippe Dro, for his years of service and contributions.
“I’m joining Scenic Biotech’s Board of Directors as the company makes great strides in advancing their lead modifier program through preclinical studies. Scenic’s approach holds significant potential in a range of neuro- and metabolic diseases and I look forward to supporting the team in bringing this approach to patients,” said Alexander Vos, Chairman of Scenic’s Board of Directors.
Alexander began his career at McKinsey & Co. in 1989 after which he joined Genzyme Europe in 1994. At Genzyme, he held several executive roles, including leading a global joint venture with Pharming NV to develop and commercialize the enzyme human alpha-glucosidase as a treatment for Pompe’s disease. Thereafter he led a number of public and private biotech companies across Europe, including two towards successful investor exits. He currently serves on the boards of several biotech companies in the USA, the United Kingdom and continental Europe. Alexander holds an MS in Pharmacy and Pharmacology from the University of Amsterdam and an MBA from Stanford University.
About Scenic Biotech
Scenic Biotech is advancing modifier therapy, a radically new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance health by acting on another function in the genome that can neutralize the disease impact, leading to a therapeutic effect. Our robust pipeline, derived from our proprietary Cell-seq platform, includes first-in-class small molecule programs that are either wholly owned or partnered through strategic collaborations with multinational pharmaceutical leaders. By unlocking new pathways in the genome, Scenic will develop a range of modifier therapies to help patients.
For more information, please contact:
Scenic Biotech
Oscar Izeboud, PhD, CEO
Phone: +31 20 705 9990
Email: oscar.izeboud@scenicbiotech.com
Trophic Communications
Eva Mulder / Desmond James
Phone: +31 6 52 33 15 79 or +49 151 6785 9086
Email: scenic@trophic.eu